Development of Levodopa Loaded Albumin Nanoparticles for Nose-to-Brain Delivery

Parkinson’s disease is a progressive neurodegenerative disorder characterized by the degeneration of dopaminergic neurons and a reduction in dopamine levels in the brain. Levodopa (L-DOPA) remains a principal pharmacological agent for the management of motor symptoms associated with Parkinson’s disease. However, its therapeutic performance may be limited by peripheral metabolism, variable systemic exposure, and challenges associated with delivering sufficient drug concentrations to the central nervous system. Intranasal administration has attracted considerable interest as a potential route for nose-to-brain drug delivery.